411 related articles for article (PubMed ID: 15087567)
1. In acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous?
Kent DM; Hinchey J; Price LL; Levine SR; Selker HP
Stroke; 2004 May; 35(5):1141-6. PubMed ID: 15087567
[TBL] [Abstract][Full Text] [Related]
2. The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
Flint AC; Gupta R; Smith WS; Kamel H; Faigeles BS; Cullen SP; Rao VA; Bath PM; Wahlgren N; Ahmed N; Donnan GA;
Int J Stroke; 2014 Aug; 9(6):705-10. PubMed ID: 25042855
[TBL] [Abstract][Full Text] [Related]
3. Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke.
Al-Khaled M; Matthis C; Eggers J
J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):7-11. PubMed ID: 22578915
[TBL] [Abstract][Full Text] [Related]
4. Hyperglycemia predicts unfavorable outcomes in acute ischemic stroke patients treated with intravenous thrombolysis among a Chinese population: A prospective cohort study.
Lin SF; Chao AC; Hu HH; Lin RT; Chen CH; Chan L; Lin HJ; Sun Y; Lin YY; Chen PL; Lin SK; Sun MH; Wei CY; Lin YT; Lee JT; Bai CH;
J Neurol Sci; 2018 May; 388():195-202. PubMed ID: 29627022
[TBL] [Abstract][Full Text] [Related]
5. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D
Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996
[TBL] [Abstract][Full Text] [Related]
6. A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke.
Adeoye O; Knight WA; Khoury J; Schmit PA; Sucharew H; Broderick JP; Pancioli AM;
J Stroke Cerebrovasc Dis; 2014; 23(5):e313-5. PubMed ID: 24534128
[TBL] [Abstract][Full Text] [Related]
7. Posterior vs. anterior circulation infarction: demography, outcomes, and frequency of hemorrhage after thrombolysis.
Dorňák T; Král M; Hazlinger M; Herzig R; Veverka T; Buřval S; Šaňák D; Zapletalová J; Antalíková K; Kaňovský P
Int J Stroke; 2015 Dec; 10(8):1224-8. PubMed ID: 26310390
[TBL] [Abstract][Full Text] [Related]
8. Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) Post Hoc Analysis.
Carr SJ; Wang X; Olavarria VV; Lavados PM; Rodriguez JA; Kim JS; Lee TH; Lindley RI; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Woodward M; Chalmers J; Anderson CS; Robinson TG;
Stroke; 2017 Sep; 48(9):2605-2609. PubMed ID: 28739832
[TBL] [Abstract][Full Text] [Related]
9. Effect of daytime, weekday and year of admission on outcome in acute ischaemic stroke patients treated with thrombolytic therapy.
Jauss M; Schütz HJ; Tanislav C; Misselwitz B; Rosenow F
Eur J Neurol; 2010 Apr; 17(4):555-61. PubMed ID: 20218973
[TBL] [Abstract][Full Text] [Related]
10. Is asymptomatic hemorrhagic transformation really innocuous?
Park JH; Ko Y; Kim WJ; Jang MS; Yang MH; Han MK; Oh CW; Park SH; Lee J; Lee J; Bae HJ; Gorelick PB
Neurology; 2012 Feb; 78(6):421-6. PubMed ID: 22282643
[TBL] [Abstract][Full Text] [Related]
11. Drop of PT Quick percent value is associated with both symptomatic and asymptomatic intracranial hemorrhage in patients treated with rt-PA for acute ischemic stroke.
Alonso A; Dempfle CE; Szabo K; Zohsel K; Hennerici MG
Thromb Res; 2011 Jan; 127(1):65-6. PubMed ID: 20537372
[No Abstract] [Full Text] [Related]
12. Time of day, outcome, and response to thrombolytic therapy: the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trial experience.
Rhoney DH; Coplin WM; Lin Y; Frankel M; Lyden PD; Levine SR
J Stroke Cerebrovasc Dis; 2010 Jan; 19(1):40-8. PubMed ID: 20123226
[TBL] [Abstract][Full Text] [Related]
13. Endovascular treatment or general treatment: how should acute ischemic stroke patients choose to benefit from them the most?: A systematic review and meta-analysis.
Yang W; Zhang L; Yao Q; Chen W; Yang W; Zhang S; He L; Li H; Zhang Y
Medicine (Baltimore); 2020 May; 99(20):e20187. PubMed ID: 32443338
[TBL] [Abstract][Full Text] [Related]
14. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
15. Thrombolytic therapy with intravenous recombinant tissue plasminogen activator in Japanese older patients with acute ischemic stroke: Fukuoka Stroke Registry.
Matsuo R; Kamouchi M; Ago T; Hata J; Shono Y; Kuroda J; Wakisaka Y; Sugimori H; Kitazono T;
Geriatr Gerontol Int; 2014 Oct; 14(4):954-9. PubMed ID: 24320947
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the Get With the Guidelines-Stroke registry.
Romano JG; Smith EE; Liang L; Gardener H; Camp S; Shuey L; Cook A; Campo-Bustillo I; Khatri P; Bhatt DL; Fonarow GC; Sacco RL; Schwamm LH
JAMA Neurol; 2015 Apr; 72(4):423-31. PubMed ID: 25642650
[TBL] [Abstract][Full Text] [Related]
17. Effect of glycated hemoglobin index and mean arterial pressure on acute ischemic stroke prognosis after intravenous thrombolysis with recombinant tissue plasminogen activator.
Liu SY; Cao WF; Wu LF; Xiang ZB; Liu SM; Liu HY; Pan Y; Nie F; Wu XM; Xie XF
Medicine (Baltimore); 2018 Dec; 97(49):e13216. PubMed ID: 30544380
[TBL] [Abstract][Full Text] [Related]
18. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study.
IMS Study Investigators
Stroke; 2004 Apr; 35(4):904-11. PubMed ID: 15017018
[TBL] [Abstract][Full Text] [Related]
19. Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset?
Kent DM; Ruthazer R; Selker HP
Stroke; 2003 Feb; 34(2):464-7. PubMed ID: 12574561
[TBL] [Abstract][Full Text] [Related]
20. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.
Hacke W; Albers G; Al-Rawi Y; Bogousslavsky J; Davalos A; Eliasziw M; Fischer M; Furlan A; Kaste M; Lees KR; Soehngen M; Warach S;
Stroke; 2005 Jan; 36(1):66-73. PubMed ID: 15569863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
